{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:03:22Z","timestamp":1793437402700,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jval.2025.03.014","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:16:58Z","timestamp":1744370218000},"page":"1018-1028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Rahul","family":"Mudumba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Nieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Padula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2025.03.014_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"18","key":"10.1016\/j.jval.2025.03.014_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jval.2025.03.014_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jval.2025.03.014_bib7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jval.2025.03.014_bib8","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of Phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.jval.2025.03.014_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jval.2025.03.014_bib10","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1177\/10781552221126174","article-title":"Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors","volume":"29","author":"Wu","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"10.1016\/j.jval.2025.03.014_bib11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40273-023-01279-2","article-title":"A systematic review of the cost-effectiveness analyses of anaplastic lymphoma kinase (ALK) inhibitors in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"41","author":"Chayab","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2025.03.014_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14737167.2023.2288249","article-title":"Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: a cost-effectiveness analysis in Greece","volume":"24","author":"Gourzoulidis","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2025.03.014_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2147\/CEOR.S415711","article-title":"Cost-effectiveness of lorlatinib for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer in Spain","volume":"15","author":"Presa","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2025.03.014_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40258-023-00807-7","article-title":"Cost-effectiveness of lorlatinib in first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden","volume":"21","author":"Naik","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2025.03.014_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241257234","article-title":"Cost-effectiveness analysis of 6 tyrosine kinase inhibitors as first-line treatment for ALK-positive NSCLC in China","volume":"18","author":"Zhang","year":"2024","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.jval.2025.03.014_bib16","article-title":"Targeting ALK rearrangements in NSCLC: current state of the art","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.014_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/1120009X.2021.1937782","article-title":"Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive\/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"34","author":"Wang","year":"2022","journal-title":"J Chemother"},{"key":"10.1016\/j.jval.2025.03.014_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754768","article-title":"Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a bayesian network meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jval.2025.03.014_bib19","doi-asserted-by":"crossref","DOI":"10.2217\/lmt-2022-0018","article-title":"Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis","volume":"12","author":"Samac\u00e1-Samac\u00e1","year":"2023","journal-title":"Lung Cancer Manag"},{"issue":"11","key":"10.1016\/j.jval.2025.03.014_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221132703","article-title":"First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis","volume":"50","author":"Tao","year":"2022","journal-title":"J Int Med Res"},{"issue":"8","key":"10.1016\/j.jval.2025.03.014_bib21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/cancers13081966","article-title":"Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-na\u00efve ALK-positive lung cancer","volume":"13","author":"Chuang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jval.2025.03.014_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221116607","article-title":"Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis","volume":"14","author":"Wen","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.03.014_bib23","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-021-08977-0","article-title":"Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jval.2025.03.014_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12885-024-11916-4","article-title":"Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.jval.2025.03.014_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/1759-7714.14824","article-title":"Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Peng","year":"2023","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.jval.2025.03.014_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jval.2017.12.017","article-title":"The ICER value framework: integrating cost effectiveness and affordability in the assessment of health care value","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2025.03.014_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2025.03.014_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.jval.2025.03.014_bib35","first-page":"970","article-title":"The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective","volume":"28","author":"Cranmer","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jval.2025.03.014_bib36","first-page":"360","article-title":"Advanced statistics: bootstrapping confidence intervals for statistics with \u201cdifficult\u201d distributions","volume":"12","author":"Haukoos","year":"2005","journal-title":"Acad Emerg Med"},{"issue":"5","key":"10.1016\/j.jval.2025.03.014_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.jval.2025.03.014_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.03.014_bib39","author":"Support"},{"issue":"8","key":"10.1016\/j.jval.2025.03.014_bib41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/13696998.2020.1762620","article-title":"Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors","volume":"23","author":"Lin","year":"2020","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2025.03.014_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cam4.1896","article-title":"Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare","volume":"8","author":"Sheehan","year":"2019","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jval.2025.03.014_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oncolo\/oyac186","article-title":"Grade 3\/4 adverse event costs of immuno-oncology combination therapies for previously untreated advanced renal cell carcinoma","volume":"28","author":"McGregor","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jval.2025.03.014_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jval.2025.03.014_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jval.2017.06.013","article-title":"A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses","volume":"21","author":"Levy","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2025.03.014_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.08.2364","article-title":"Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer","volume":"17","author":"Roughley","year":"2014","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2025.03.014_bib49","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2025.03.014_bib50","first-page":"514","article-title":"Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective","volume":"24","author":"Mistry","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.jval.2025.03.014_bib51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Mak"},{"issue":"12","key":"10.1016\/j.jval.2025.03.014_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.10.3748","article-title":"Real-world medical utilization and outcomes associated with treatments for advanced ALK-positive non-small cell lung cancer","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2025.03.014_bib53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2025.03.014_bib54","article-title":"Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.jval.2025.03.014_bib55","article-title":"Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: a brief report","volume":"4","author":"Thummalapalli","year":"2023","journal-title":"JTO Clin Res Rep"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525022843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525022843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:53:06Z","timestamp":1782964386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525022843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1098301525022843"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.014","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}